Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age≧20 years old~2. Life expectancy≧3 months~3. Eastern Cooperative Oncology group (ECOG) score 0\~2~4. Cytologically-or histologically-confirmed non-small cell lung cancer（NSCLC)~5. Patients with clinical TNM classification of Malignant Tumours (TNM) stage IV...~Exclusion Criteria:~1. Patients with history of cardiovascular disease, including uncontrolled hypertension, congestive heart failure, myocardial infarction, angina pectoris, coronary artery disease, uncontrolled arrhythmia , previous history of encephalopathy within the past six months of screening period~2. Patients with HIV, HTLV or active tuberculosis~3. Women who are pregnant or breast-feeding~4. Patients with drug or other substance abuse~5. Patients with any other major disease, serious organ failure or patients unfit for participating in the trial (by the investigator's judgment)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): 26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).